can also affect children. Current treatment of psoriatic arthritis is similar to that of rheumatoid arthritis.

[0007] A significant angiogenesis-related disease is cancer. Cancer is the second leading cause of death in the United States and accounts for over one-fifth of all mortality. Although a variety of methods are known to treat cancer, including surgical resection of solid tumors, and radiation, ablation and chemotherapy to kill cancerous cells, local recurrence of cancerous cells and local damage or disease at the resected or treated site remain major challenges in the treatment of cancer patients. Surgical resection represents the greatest chance to treat localized disease that has not shown signs of metastasis to other locations in the body. Unfortunately, as many as 40% of cancer patients treated with surgical resection will develop a recurrence of the disease.

[0008] Current treatments for angiogenesis-related conditions and diseases and neovascularization-related conditions and diseases are limited. Treatment options vary with age, health, and the severity of the condition. One objective of the present invention is to provide methods and materials for the treatment of sites of abnormal neovascularization and pathological angiogenesis with the goal of locally directing healing of the affected or treated site.

Summary ~~of the Invention~~

[0008a] In one aspect, there is provided the use of implantable material in the manufacture of a medicament for treating a tumor resection site in an individual in need thereof, said use comprising the step of: contacting with an implantable material a surface at or adjacent to or in the vicinity of a tumor resection site, wherein said implantable material comprises a biocompatible matrix and cells and further wherein said implantable material is in an amount effective to treat the tumor resection site in said individual.

[0008b] In another aspect, there is provided a composition for the treatment or management of a tumor resection site, the composition comprising a biocompatible matrix and cells, wherein said composition is in an amount effective to treat or manage the tumor resection site.

[0009] The present disclosure~~invention~~ exploits the discovery that an implantable material comprising cells and a biocompatible matrix, when provided locally to a site of abnormal neovascularization or a site of pathological angiogenesis, can prevent, reduce or inhibit abnormal or pathological blood vessel formation, inflammation, extracellular matrix degradation and/or MMP expression and/or activation at the site to treat the affected or treated tissue or stroma and/or to prevent the growth or regrowth of pathological vasculature or other tissue at the affected or treated site. As disclosed herein, an implantable material comprising cells, preferably endothelial cells, cells having an endothelial-like phenotype, epithelial cells, cells having an epithelial-like phenotype, non-endothelial cells or analogs thereof can be used to prevent, heal, treat and manage sites of abnormal

neovascularization or pathological angiogenesis when the material is situated on a surface of or within an affected or treated structure. This discovery permits the clinician to intervene in the treatment of a diseased tissue for which there have heretofore been limited treatment options.

[0010] One embodimentaspect of the present disclosureinvention is a method of treating a site of pathological angiogenesis in an individual in need thereof, the method comprising contacting with an implantable material a surface at or adjacent to or in the vicinity of an area of angiogenesis, wherein said implantable material comprises a biocompatible matrix and cells and further wherein said implantable material is in an amount effective to treat the site of pathological angiogenesis in said individual.

[0011] According to additional embodiments, the biocompatible matrix is a flexible planar material or a flowable composition. The cells can be endothelial cells, endothelial-like cells, epithelial cells, epithelial-like cells or non-endothelial cells.

[0012] According to various embodiments, the implantable material regulates extracellular matrix degradation at the site of pathological angiogenesis, or regulates the expression and/or activation of MMPs at the site of pathological angiogenesis. According to one embodiment, the site of pathological angiogenesis is a site of tumor resection.

[0013] In another embodimentaspect, the disclosureinvention is a composition suitable for the treatment or management of a site of abnormal neovascularization, the composition comprising a biocompatible matrix and cells, wherein said composition is in an amount effective to treat or manage the site of abnormal neovascularization.

[0014] According to additional embodiments, the biocompatible matrix is a flexible planar material or a flowable composition. The flowable composition can further comprise an attachment peptide and the cells are engrafted on or to the attachment peptide. The cells can be endothelial cells, endothelial-like cells, epithelial cells, epithelial-like cells or non-endothelial cells.

[0015] According to various embodiments, the composition regulates extracellular matrix degradation at the site of pathological angiogenesis or regulates expression and/or activation of MMPs at the site of pathological angiogenesis.

[0016] Another embodimentaspect of the present disclosureinvention is a method of treating a site of abnormal neovascularization in an individual in need thereof, the method comprising contacting with an implantable material a surface at or adjacent to or in the vicinity of an area of abnormal neovascularization, wherein said implantable material comprises a biocompatible matrix and cells and further wherein said implantable material is in an amount effective to treat the site of abnormal neovascularization in said individual.

[0017] According to additional embodiments, the biocompatible matrix is a flexible planar material or a flowable composition. The cells can be endothelial cells, endothelial-like cells, epithelial cells, epithelial-like cells or non-endothelial cells.

[0018] According to various embodiments, the implantable material regulates extracellular matrix degradation at the site of abnormal neovascularization or regulates expression of MMPs at the site of abnormal neovascularization.

[0019] According to various embodiments, the site of abnormal neovascularization is a site of macular degeneration, a site of rheumatoid arthritis, a site of psoriasis, a site of psoriatic arthritis, or a site of another systemic inflammatory disease.

[0020] In another embodimentaspect, the disclosureinvention is a composition suitable for the treatment or management of a site of abnormal neovascularization, the composition comprising a biocompatible matrix and cells, wherein said composition is in an amount effective to treat or manage the site of abnormal neovascularization.

[0021] According to additional embodiments, the biocompatible matrix is a flexible planar material or a flowable composition. The flowable composition can further comprise an attachment peptide and the cells are engrafted on or to the